Literature DB >> 9160512

Urea/DTT solubilization of a recombinant Taenia ovis antigen, 45W, expressed as a GST fusion protein results in enhanced protective immune response to the 45W moiety.

J S Rothel1, P R Wood, H F Seow, M W Lightowlers.   

Abstract

Vaccination and challenge infection experiments were conducted in sheep using different forms of a recombinant protein (45W) from the cestode parasite Taenia ovis. 45W was expressed in Escherichia coli as a fusion protein with glutathione-S-transferase (45W-GST) and was produced as both soluble protein and insoluble inclusion bodies. Vaccination of animals with either the soluble or inclusion body derived protein resulted in the immune response being predominantly directed to the GST moiety of 45W-GST. Conversely, vaccination with 45W-GST which had been solubilized/treated with urea and dithiothreitol (DTT), elicited enhanced responses to the 45W moiety and significantly reduced responses to GST. Vaccination with all forms of 45W-GST protected sheep against experimental T. ovis infection. However, protection was highly correlated with anti-45W antibody levels and these were significantly higher in animals vaccinated with the urea/DTT treated form of 45W-GST. It is suggested that recombinant proteins expressed either with or without fusion partners may stimulate enhanced immune responses when incorporated in vaccine formulations in a denatured/reduced state.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160512     DOI: 10.1016/s0264-410x(96)00229-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA.

Authors:  N Orr; J E Galen; M M Levine
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Protection of pigs against Taenia solium cysticercosis by immunization with novel recombinant antigens.

Authors:  Charles G Gauci; César M Jayashi; Armando E Gonzalez; Julia Lackenby; Marshall W Lightowlers
Journal:  Vaccine       Date:  2012-04-19       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.